english.prescrire.org > Spotlight > 100 most recent > In-utero exposure to lamotrigine: better elucidated consequences

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In-utero exposure to lamotrigine: better elucidated consequences

 Adverse Effects  In 2019, lamotrigine was the most thoroughly evaluated antiepileptic drug in terms of the consequences of in-utero exposure, and it seemed to be the least teratogenic antiepileptic. The rate of major malformations associated with doses below 300 mg per day was similar to that observed in the general population. In the long term, in-utero exposure to lamotrigine seemed to increase the incidence of neurodevelopmental disorders. What more is known in 2026 about the consequences of in-utero exposure to lamotrigine?
Full article available for download by subscribers

 ©Prescrire 1 June 2026

Source: "In-utero exposure to lamotrigine: better elucidated consequences" Prescrire Int 2026; 35 (282): 159-160. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"Antiepileptics and pregnancy:
potential long-term effects
in children"
Prescrire Int 2020;
29 (211): 13-20. 
Subscribers only
"Valproic acid in utero:
autism"
Prescrire Int 2014;
23 (147): 72.
Subscribers only